4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-25-018116
CHIEF SCIENTIFIC OFFICER sold 12,500 shares at $21.40 ($267,458)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER
Table I: Non-derivative
1 line| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2025-06-20 | Sale : show line 1 in the form 10b5-1 | −12,500 | $21.40 | $267,458 | 965,188 | I |
| Open-market sales · 12,500 sh · avg $21.40 · $267,458 | ||||||
Loading xslF345X05/form4-06242025_090617.xml…